Merck: completes acquisition of Tilos Therapeutics

(CercleFinance.com) - Merck has announced signing a definitive agreement to acquire Tilos Therapeutics.


This private biopharmaceutical company develops treatments targeting the latent TGFβ complex for the treatment of cancer, fibrosis and auto-immune diseases.

Merck will acquire all Tilos' outstanding shares for up to 773 million dollars, including an upfront payment and milestone payments.

Dr. Barbara Fox, CEO at Tilos said that, "This agreement with Merck, an industry leader in biopharmaceutical research and development, provides meaningful validation for our therapeutic approach and best positions our pipeline for broad clinical and commercial success."



Copyright (c) 2019 CercleFinance.com. All rights reserved.